Absci Corp - Asset Resilience Ratio
Absci Corp (ABSI) has an Asset Resilience Ratio of 59.86% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Absci Corp (ABSI) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Absci Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ABSI asset base.
Liquid Assets Composition Over Time
This chart breaks down Absci Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Absci Corp (ABSI) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $117.08 Million | 59.86% |
| Total Liquid Assets | $117.08 Million | 59.86% |
Asset Resilience Insights
- Very High Liquidity: Absci Corp maintains exceptional liquid asset reserves at 59.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Absci Corp Industry Peers by Asset Resilience Ratio
Compare Absci Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Absci Corp (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Absci Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.45% | $124.27 Million | $216.30 Million | +24.11pp |
| 2024-12-31 | 33.34% | $71.21 Million | $213.61 Million | +21.70pp |
| 2023-12-31 | 11.64% | $25.30 Million | $217.30 Million | -20.90pp |
| 2022-12-31 | 32.55% | $104.48 Million | $321.01 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $426.19 Million | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more